Introduction 1 2
Multiple sclerosis (MS) is a chronic inflammatory disease in which T cells breach the blood-brain barrier and 3 mount an attack against central nervous system (CNS) myelin. MS, which affects more than 2 million people 4 world-wide (Browne et al., 2014) , presents two broad clinical courses: relapsing/remitting (RR) or progressive. 5
A number of immunomodulatory therapies are now available for RR disease, which is seen in approximately 6 80% of patients from onset (Scalfari et al., 2013) . However, 30-60% of MS patients will ultimately transition to 7 a secondary progressive (SP) form of the disease for which current drugs are largely ineffective (Larochelle et 8 al., 2016) . 9
The role of biological sex as a determinant of MS incidence is well established, as women develop the 10 disease at 2-3 times the frequency of men (Greer and McCombe, 2011; Sloka et al., 2011) . However, what is 11 less well understood is why MS in men tends to progress more rapidly and aggressively (Beatty and Aupperle, 12 2002; Menon et al., 2013; Tremlett et al., 2006) . In parallel, it is increasingly more appreciated that T helper 17 13 (Th17) CD4 + T cell responses may be drivers of progressive MS (Huber et al., 2014; Romme Christensen et al., 14 2013) , though the mechanisms remain unclear. Together, these clinical findings illustrate the uncoupling of 15 disease incidence and severity in MS, and underscore the need for deciphering the cellular and molecular 16 mechanisms underlying the role of biological sex in determining disease course in MS. 17
Experimental autoimmune encephalomyelitis (EAE) is a mouse model that recapitulates key immune 18 aspects of MS. It can be induced by active immunization by encephalitogenic myelin-derived peptides, as well 19
by the adoptive transfer of primed myelin-reactive T cells, with the latter approach permitting one to isolate the 20 role of T cells, and specific effector T cell subsets, in disease processes (Jäger et al., 2009; Rangachari et al., 21 2012) . The popular C57BL6/J model of EAE displays either an acute monophasic or stably chronic disease 22 course (Berard et al., 2010) , while EAE in SJL/J mice shows a RR pattern (McRae et al., 1995) . By contrast, 23 numerous groups have shown that active immunization of non-obese diabetic (NOD) strain mice with myelin 24 oligodendrocyte glycoprotein (MOG) induces a RR disease course followed by transition to chronic 25 disease. Accordingly, the NOD-EAE active immunization model has been used to probe potential mechanisms 1 driving progressive disease (Farez et al., 2009; Mayo et al., 2014) . 2
In this study, we used a T cell receptor (TcR) transgenic (Tg) model (1C6), that recognizes MOG 3 on the NOD background (Anderson et al., 2012) , to examine the role of biological sex in determining Th17 4 phenotype and disease course upon adoptive transfer into NOD.Scid mice. We observed a striking sex bias, as 5 recipients of male 1C6 Th17 cells developed disease of greater severity than recipients of female Th17 cells, 6
characterized by a higher frequency of progressive disease. This sex dimorphism was T cell-intrinsic, as male 7
Th17 cells induced severe disease irrespective of whether they were transferred to male or female recipients. 8
Male Th17 cells displayed a strong tendency towards production of interferon (IFN)-γ upon adoptive transfer, 9
and they developed an "ex-Th17" transcriptional signature that is associated with Th17 cell pathogenicity. 10
Notably, male Th17 pathogenicity was driven my male sex chromosomal complement rather than by androgens; 11
we identified an X-linked immunomodulatory gene, Jarid1c, which escapes second-copy silencing in female 12 immune cells and is downregulated in both male 1C6 Th17 cells that transfer severe EAE. Interestingly, the 13 downregulation of Jarid1c was also observed in CD4 + T cells taken from male patients with MS. We thus 14 uncover a molecular and cellular basis for the association of male sex with exacerbated disease course in CNS 15
autoimmunity. 16 17

Results
19
Male 1C6 Th17 cells induce severe and frequently lethal progressive EAE 20
Multiple lines of evidence indicate a role for dysregulated Th17 responses in progressive MS. CD4 + IL-23R
Th17 cells are increased in the peripheral blood of SPMS and primary progressive (PP) MS, but not RRMS, 22
patients (Romme Christensen et al., 2013) . Further, circulating levels of Th17-inducible chemokines are higher 23 in SPMS as compared to RRMS (Huber et al., 2014) . However, while MS progresses more rapidly in men, the 24 potential contribution of biological sex to Th17-driven relapsing/remitting and chronic progressive CNS 25 autoimmune inflammation has not been extensively studied. 26
To examine this, we developed an adoptive transfer protocol in which we first purified splenic and 1 lymph node CD4 + CD62L hi cells from female or male 1C6 mice and stimulated them for 5 days with agonistic 2 antibodies to CD3 and CD28 under established pathogenic Th17 differentiation conditions (Bettelli et al., 2006 ) 3 ( Figure 1A ). By using an antibody stimulation approach, rather than stimulation via peptide and antigen-4 presenting cells, we were able to isolate the contributions of T cells alone to disease processes. After 5 days of 5 in vitro culture, both female and male Th17 cells were highly positive for the Th17 master transcription factor 6 RORγt ( Figure 1B ), indicating that they were committed to the Th17 lineage prior to in vivo transfer. We then 7 adoptively transferred 1C6 Th17 cells to sex-matched NOD.Scid recipient mice and monitored them for signs of 8 clinical disease over the course of 70 days. Use of NOD.Scid mice as hosts carried several distinct advantages. 9
First, NOD.Scid are resistant to the development of spontaneous diabetes that is characteristic of the NOD strain 10 ( Bobbala et al., 2012; Christianson et al., 1993; Rohane et al., 1995) and thus we could exclude insulitis and 11 beta-cell destruction as confounding factors that could affect the course of EAE. Further, the lack of 12 endogenous T cells in NOD.Scid mice allowed us to conduct sex-mismatched transfers without fear of host-13 versus-graft reactivity. 14 Strikingly, adoptive transfer of male 1C6 Th17 cells to male NOD.Scid induced EAE of much greater 15 severity overall than that seen when female 1C6 Th17 were transferred to female NOD.Scid (Table 1) . More 16 than two-thirds of male Th17 recipients (M rapid ) developed a chronically worsening disease course and rapidly 17 attained ethical endpoints (33.7 d ± 2.5). The remaining males developed a non-lethal course (M d70 ) that did not 18 differ in severity from female (F) Th17 recipients ( Figure 1C , Table 1 ). All female Th17 recipients survived to 19 d70. These data gave the first indication that male Th17 cells have a greater intrinsic pathogenic capacity. 20
Irrespective of sex, more than half of all Th17 recipients (35/63) developed chronically worsening 21 disease, while close to a third (19/63) displayed at least one relapse/remission cycle followed by chronic 22 worsening of symptoms. Thus, a substantial frequency of 1C6 Th17 recipients recapitulated the biphasic disease 23 course that is observed in actively immunized NOD animals. Further, as NOD.Scid mice do not develop 24 diabetes, this also indicated that biphasic disease could develop independently of the insulitis and beta cell 25 destruction that characterizes the NOD strain. 26 visible disease. Nevertheless, the percentage of IFNγ-producing male splenic cells was again significantly 1 higher than that observed of females at relapse (Fig 2D) . Thus, despite being committed to the Th17 lineage 2 prior to adoptive transfer (Fig 1B) , transferred Th17 cells, and male Th17 cells in particular rapidly exhibited 3 phenotypic plasticity in the in vivo setting. 4
To examine whether sex-specific differences could be observed in the target organ, we next measured 5 cytokine production of T cells entering the CNS at onset and relapse. At both timepoints, the vast majority of T 6 cells, both male and female, produced no IL-17 and rather displayed an IL-17 -IFNγ + phenotype ( Figure 2E ), 7
indicating the superior capacity of these cells to enter the target organ. However, there were no significant 8 differences between the proportions of either IL-17 -IFNγ + or total IFNγ + between the sexes at these timepoints. 9
Granulocyte and macrophage colony-stimulating factor (GM-CSF) is a crucial positive regulator of 10 Th17 cell pathogenicity in both MS and EAE (Becher et al., 2016) . As we had observed phenotypic plasticity in 11 male Th17 cells in early disease, we next sought to determine whether male cells produced more of this 12 cytokine. However, no differences in GM-CSF expression between male and female Th17 cells were seen at 13 disease onset or relapse or in either splenic (Supplemental Figure 1A) or CNS (Supplemental Figure 1B) T 14 cells. Similarly, few differences were observed between male and female with respect to TNFα and IL-2 15 production, though a higher percentage of male splenic Th17 produced TNFα at relapse (Supplemental Figure  16 1A). We could also rule out an increased conversion of female Th17 to FoxP3 + T reg , as no differences in the 17 frequency of these cells was observed between males and females (Supplemental Figure 1C) . 18
19
Phenotypic plasticity of male Th17 cells underlies a rapid disease course. 20
Our data thus showed important differences between transferred male versus female T cells during early 21 disease timepoints. A substantially greater proportion of splenic male Th17 produced the heterodox cytokine 22
IFNγ as compared to females. This indicated that male Th17 more rapidly adopted a plastic phenotype in vivo. 23
However, in the CNS, no differences in IFNγ production were observed between recipients of male or female 24 cells at these timepoints, reflecting the similar kinetics of symptom onset between the two groups. By contrast, 25
we had observed a sex dimorphism at disease endpoint. Mice receiving female 1C6 Th17 universally survived 26 to d70 with disease of moderately severe maximal severity (score 2.6 ± 0.2; Table 1), while there were two 1 possible fates for mice that received male Th17: the majority rapidly attained ethical endpoints (M rapid ), while a 2 minority survived to d70 (M d70 ) and had disease of comparable severity to those receiving female (F) Th17 3 ( Figure 1C ). 4
We thus examined whether increased Th17 phenotypic plasticity might explain these divergent 5 outcomes, by comparing IL-17 and IFNγ production from T cells isolated from F Th17, M rapid and M d70 6 recipients. In all conditions, as predicted our findings at relapse, the majority of cytokine-producing T cells in 7 both spleen and CNS were IL-17 -IFNγ + . The percentage of splenic Th17 making IFNγ was increased from 8 M rapid mice relative to those from female and M d70 ( Figure 3A ). By contrast, no differences in IL-17 production 9
were observed. Crucially, we saw a large increase in the frequency of IFNγ + T cells in the CNS of M rapid mice, 10 as compared to either F or M d70 mice ( Figure 3B ). Further, CNS-infiltrating Th17 from M rapid made over 12-fold 11 more IFNγ than either female or M d70 cells as measured by mean fluorescence intensity (MFI). MFI of GM-12 CSF, but not of TNFα or IL-2, was also significantly increased from M rapid T cells ( Figure 3C ). Altogether, our 13 data showed that male sex is an important regulator of Th17 plasticity, and that Th17 production of IFNγ and 14 GM-CSF correlates strongly with disease severity observed in recipients of male Th17. 15
16
Male Th1 cells do not induce a rapid disease course 17
We had found that male Th17 cells induced severe EAE and were highly plastic as characterized by 18 their heightened production of IFNγ relative to female Th17 cells. We therefore wanted to ascertain whether a 19 similar sex dimorphism applies to Th1 cells, which are bonafide IFNγ producers and are also potent inducers of 20 EAE in adoptive transfer models (Jäger et al., 2009; Rangachari et al., 2012) . We stimulated male and female 21 naïve 1C6 CD4 + CD62L hi cells with agonistic anti-CD3 and anti-CD28 and under defined Th1 differentiation 22 conditions (Rangachari et al., 2012) . After 5 days of culture, the resulting cells were positive for T-bet ( Figure  23 4A), the master Th1 lineage transcription factor (Szabo et al., 2000) . We then transferred these Th1 cells to sex-24 matched NOD.Scid recipient mice. Linear regression analysis of the disease curves of host mice suggested that 25 male 1C6 Th1 recipients accumulate symptoms more rapidly than those receiving female Th1 cells ( Figure 4B ), 26 and maximal disease severity was also higher in mice receiving male Th1 cells (Table 1) . Crucially, however, 1 disease severity of male Th1 recipients was significantly lower than that of male Th17 recipients (Table 1) , and 2 a greatly reduced proportion of male Th1 recipients experienced a rapid disease course in which mice attained 3 ethical endpoints before 70 days (Table 1) . In sum, our data indicated that a sex dimorphism by which male 1C6 4 Th1 cells worsen the course of EAE relative to female Th1; however, male Th17 cells were required for an 5 extremely severe, accelerated, progressive disease course. 6 7 Male sex interacts with disease duration, but not severity, in augmenting an ex-Th17 signature. 8
In recent years, there has been intense interest in characterizing diverse Th17 cell fates at the transcriptional 9 level. In an important advance, single cell RNA-seq analyses revealed that Th17 cells can be classified into 10 successive transient states, adopting a Th1-like "ex-Th17" transcriptional profile ("pre-Th1-like" à 11 "Th17/Th1-like" à "Th1-like memory") as they become pathogenic in C57BL/6J EAE (Gaublomme et al., 12 2015) . We therefore examined whether signature transcripts from these cellular states were upregulated in male 13 Th17 cells. We observed that only 2 of 13 targets -Il18r1 and Cxcr6 -were upregulated in splenic male Th17 14 cells at disease onset (Supplementary Figure 2) . Thus, male Th17 did not appear to have initiated a transition 15 towards an ex-Th17 transcriptional profile at the first signs of clinical symptoms, despite a greater frequency of 16 male Th17 being IFNγ + at this timepoint. 17
We next examined whether the presence of an ex-Th17 transcriptional profile correlated with 18 exacerbated disease outcomes. We compared males that developed rapid, fatal disease (M rapid ) to females that 19 we sacrificed in parallel (F early ). In agreement with our previous findings, F early mice did not show signs of 20 severe disease ( Figure 5A ). We additionally compared males and females that survived to d70 (M d70 vs F d70 ). 21
As expected, M d70 had disease of comparable severity to F d70 ( Figure 5B ). We then assessed expression of 22 candidate pre-Th1-like ( Figure 5C ), Th17/Th1-like ( Figure 5D ) and Th1-like memory ( Figure 5E ) transcripts 23 from splenic CD4 + T cells by qPCR. Of the 13 signature transcripts studied, 5 were upregulated in M rapid Th17 24 cells relative to F early Th17. Notably, these transcripts included the cell surface receptors IL18r1 and Ccr2 25 ( Figure 5C ), and Ifngr1 and IL2rb ( Figure 5E ). To our surprise, M d70 Th17 showed strong induction of each 26 stage of the ex-Th17 gene program, despite the fact that these cells transferred EAE of a moderate, non-rapid 1 disease course: eleven transcripts were upregulated in M d70 Th17 relative to F d70 Th17, with Il2ra and Samsn1 2 being the sole exceptions. Furthermore, 8 transcripts (Mina, Fas, Ccr2, Tnfsf11, Ifngr1, Nr4a1, Tigit, Il1r2, 3 Il2ra, Samsn1) were upregulated in M d70 Th17 as compared to M rapid that induced severe disease -in some 4 cases dramatically ( Figures 5C-E) . Only 3 of these 8 transcripts (Ifngr1, Il2ra, Samsn1) were similarly 5 upregulated in F d70 versus F early , indicating that the correlation between disease duration and pathogenic gene 6 upregulation was principally driven by male sex. Thus, while male sex augments an ex-Th17 gene signature in 7 1C6 Th17 cells, it does so in relation to disease duration and not to disease severity. Further, the increased 8 production of IFNγ by male Th17 cells that induced rapid, severe, EAE could be uncoupled from the ex-Th17 9 transcriptional signature. 10
11
Inflammasome inhibition modulates the severity of male Th17-induced disease 12
We next wanted to identify molecules and/or pathways that could be targeted so as to attenuate the severity of 13 disease in male Th17 cell recipients. We noted that the pre-Th1-like signature transcript Il18r1 was upregulated 14 by more than 2-fold in M rapid Th17 as compared to F early ( Figure 5C ), and thus might be a possible target. IL-15 18/IL-18R signaling lies downstream of caspase-1-dependent inflammasome activation, and it was recently 16
shown that the caspase-1 inhibitor VX-765 reduced both inflammasome activation and IL-18 secretion, and 17 improved behavioral outcomes, in the acute C57BL/6J model of EAE (McKenzie et al., 2018) . We therefore 18 asked whether inhibiting inflammasome activation in vivo could modulate the severe disease induced by male 19 Th17. We transferred male Th17 to male recipients and began treating the mice with VX-765 or vehicle daily 20 once they reached a clinical score of 2 (impaired righting reflex). VX-765 significantly ameliorated the 21 accumulation of disease symptoms in recipient mice with established EAE (Figure 5F ), indicating that 22 activation of the inflammasome activity is important for the development of severe disease induced by male 23 1C6 Th17. 24
25
Chromosome complement exacerbates NOD-EAE in males 26
Sex hormones can have profound effects on the pathogenesis of EAE (Dunn et al., 2015) . It was therefore 1 possible that androgens were responsible for the severe EAE induced by male Th17. We generated Th17 cells 2 from male 1C6 mice that had been castrated (Th17 M cast ) or sham-operated (Th17 M sham ), and adoptively 3 transferred them to male NOD.Scid mice. Interestingly, we observed that transfer of Th17 cast did not reduce 4 disease severity ( Figure 6A ), indicating that T cell-intrinsic androgens were not pathogenic. We next tested the 5 pathogenicity of Th17 from female 1C6 that had been ovariectomized (Th17 F ovx ) or sham-operated (Th17 6 F sham ), and found that removal of female sex hormones did not worsen EAE in female transfer recipients (Figure  7 6B). These data showed that differences in pathogenicity between male and female Th17 were not due to sex 8
hormones. 9
Sex chromosome complement (XX vs XY) can also play an important role in regulating immune 10 responses (Rubtsov et al., 2010) . To assess the role of chromosome complement in the presence of androgen, 11
we exploited the Four Core Genotype (FCG) model (Arnold and Chen, 2009) , in which the testes-determining 12 gene Sry is knocked out of the Y chromosome (Y SryKO ), but is knocked in to an autosomal chromosome (Tg-13 Sry). We generated F1 NOD x C57BL/6J (B6) Tg-Sry XY SryKO mice, which produce androgens and are 14 chromosomally male, as well as Tg-Sry XX mice, which produce androgens yet are chromosomally female. We 15 then actively immunized these mice with MOG and observed their development of EAE, exploiting the 16 prior observation that NOD x B6 F1 mice phenocopy NOD-EAE upon immunization with this encephalitogenic 17 epitope. (Mayo et al., 2014; 2016) . We found that Tg-Sry XY SryKO mice developed disease of dramatically 18 greater severity than Tg-Sry XX ( Figure 6C ). Intriguingly, a substantial frequency of CNS-infiltrating CD4 + T 19 cells in Tg-Sry XY SryKO mice displayed a IL-17 + IFNγ + phenotype ( Figure 6D ), which is reflective of Th17 20 plasticity (Carbajal et al., 2015; Hirota et al., 2011) Mammalian female cells inactivate one of their two X-chromosomes, thus ensuring equivalent dosage of X-9 linked genes between the sexes. However, this process is far from total (Arnold et al., 2016) and numerous 10 genes on the silenced X chromosome continue to be transcribed in a tissue-specific manner (Berletch et al., 11 2015) . Thus, differential dosage of X-linked genes may help explain differences in immune function in females 12 versus males. As our data indicated that male sex chromosome complement exacerbated Th17 pathogenicity 13 ( Figure 6E ), we hypothesized that X-linked genes might a) repress Th17 pathogenicity, and b) be 14 downregulated in male Th17 cells. To study this possibility, we analyzed publicly available RNA-seq datasets 15 of lymph node and CNS-infiltrating Th17 at the peak of C57BL6/J EAE (Gaublomme et al., 2015) . We 16 considered CNS-infiltrating Th17 cells to be pathogenic, as they had infiltrated the target organ. Conversely, 17 lymph node Th17 were considered non-pathogenic. We identified a set of transcripts on the X chromosome that 18 were downregulated by 2-fold or greater in CNS Th17 (Supplementary Table 1 ) and thus could be inhibitors of 19 Th17 pathogenicity. We then compared these transcripts to a set of X chromosome genes that were previously 20 shown to escape second-copy silencing in female mouse spleen (Berletch et al., 2015) , thereby identifying three 21 X-linked transcripts, Jarid1c, Utp14a and Pbdc1 ( Figure 7A ) that might explain differences in pathogenicity 22 between male and female Th17. Intriguingly, it was recently reported that Jarid1c negatively regulates dendritic 23 cell activation, suggesting that it can suppress immune cell function (Boukhaled et al., 2016) . 24
We next asked whether these putative immunomodulatory X-linked candidates were downregulated in 25 pathogenic male Th17 that induce severe disease. We found that Jarid1c was specifically downregulated in 26 CNS-infiltrating Th17 cells from M rapid recipients that develop early, severe disease, as compared to CNS-1 infiltrating cells from F early mice. ( Figure 7B ). However, there were no differences in Jarid1c expression 2 between Th17 cells from M d70 and F d70 that developed mild disease of comparable severity. Utp14a was 3 downregulated in both M rapid and M d70 as compared to timepoint-matched female controls, while Pbdc1 was 4 only downregulated in M d70 ( Figure 7B ). 5
We next examined whether sex differences could be observed in the expression of X-linked immune 6 regulators in the context of human MS. We therefore examined expression of Jarid1c, Utp14a and Pbdc1 in 7 purified CD4 + T cells from age-matched men (51.4 ± 1.5a) and women (52.6 ± 2.2a) living with MS 8 (Supplementary Table 2 ). We observed lower Jarid1c expression in CD4 + T cells from men ( Figure 7C ). No 9 sex differences were observed in the expression of Utp14a and Pbdc1. Together, our data showed that male sex 10 complement can worsen progressive EAE, and that the X-linked immunoregulatory gene Jarid1c is 11 downregulated both in pathogenic tissue-infiltrating male Th17 as well as in CD4 + T cells from men with MS. 12
13
Discussion 14
As is the case for many autoimmune diseases, the incidence of RRMS is much (up to 3 times) greater in 15 women than in men (Orton et al., 2006) . Nevertheless, men are more likely to progress to a higher level of MS 16 disability than women, and male sex is an exacerbating factor for conversion of RR to SP MS (Koch et al., 17 2010). As NOD mice develop a chronic progressive form of EAE (Farez et al., 2009; Mayo et al., 2014) , we 18
developed an adoptive transfer model on this background to examine whether male sex could increase the 19 incidence and severity of progressive disease in a T cell-intrinsic manner. 20
We find that recipients of male 1C6 Th17 develop EAE of greater severity than their female 21 counterparts, also developing chronically progressive disease at a higher frequency. While the majority of 22 recipients of male Th17 attain experimental endpoints rapidly, a subset of mice displays disease that is of no 23 greater severity than that of recipients of female Th17. This is important because it allowed us to identify 24 factors that drive worsened pathology in our model. Further, our data show that enhanced disease in males is 25 due to T cell-intrinsic effects, as male 1C6 Th17 cells induce EAE of markedly great severity relative to females 26 regardless of whether they are transferred to male or female hosts. At first glance, this may seem surprising, 1
given that women display a higher CD4 + T cell count than men, and that female cells proliferate more robustly 2 upon antigenic stimulation. On the other hand, multiple lines of evidence in mouse (Jane-wit et al., 2008; Li et 3 al., 2013; Zhang et al., 2012) and man (Gracey et al., 2016; Yi et al., 2009; Zhang et al., 2012) indicate that 4 male sex can promote Th17 responses in the context of autoimmunity. Notably, we found that IFNγ production 5 was considerably greater in peripheral male 1C6 Th17 cells at all timepoints studied and crucially, CNS-6 infiltrating male Th17 cells were highly positive for IFNγ and GM-CSF in mice that develop severe endstage 7 disease. Thus, we demonstrate, for the first time, a role for male sex in augmenting Th17 phenotypic plasticity, 8 which is itself an important determinant of disease severity in autoimmunity (Abromson-Leeman et al., 2009; 9 Carbajal et al., 2015; Y. K. Lee et al., 2009; Suryani and Sutton, 2007) . It is worth noting that while female 1C6 10 Th17 produced less IFNγ in vivo than their male counterparts, they also turned off IL-17 expression by the first 11
relapse. This may be characteristic of T cells on the NOD background, as NOD-strain pancreatic Ag-specific 12
Th17 cells are prone to converting to an IL-17 -IFNγ + phenotype upon transfer to NOD.Scid, and blocking IFNγ 13 could rescue Th17-induced diabetes in this model (Bending et al., 2009; Martin-Orozco et al., 2009) . 14 In recent years, increasing attention has been paid to the transcriptional profile of Th17 cells 15 (Gaublomme et al., 2015; Yosef et al., 2013) , with the goal of identifying functional gene modules that dictate 16 whether or not they become pathogenic in the context of tissue inflammation. We found that ex-Th17 17 transcriptional markers were increased in adoptive transferred male Th17 cells, supporting the view that male 18 sex enhances Th17 plasticity. Interestingly, while these markers were initially described as correlating with 19 increased pathogenicity in the context of EAE (Gaublomme et al., 2015) , we found that while some were indeed 20 upregulated in male Th17 that transferred severe disease, they were more strongly associated with male Th17 21 that induced relatively milder disease in recipients that survived to d70. A potential explanation for this 22 discrepancy is that these targets were initially identified using an IL-17-GFP reporter mouse strain in which 23
Th17 cells were actively generating IL-17 at the time of harvest (Gaublomme et al., 2015) . We, on the other 24 hand, observe that adoptively transferred 1C6 Th17 lose IL-17 expression relatively early on in disease. Thus, it 25 is possible that this transcriptional signature may correlate with plasticity, but not necessarily pathogenicity, in 26 Th17 cells that have lost IL-17 expression entirely. Importantly, IFNγ (Abromson-Leeman et al., 2009; Carbajal 1 et al., 2015; Hirota et al., 2011; Suryani and Sutton, 2007) and GM-CSF (Becher et al., 2016) , which are 2 functional markers of pathogenic Th17 cells, are strongly upregulated in male Th17 that transfer severe disease, 3
suggesting that pathogenicity of these cells may be uncoupled from transcriptionally-defined plasticity in our 4 model. Another important question is why a proportion (~30%) of male Th17 recipients develop only mild 5 disease. Overall, splenic CD4
+ from male Th17 recipients showed increased IFNγ at onset and relapse; it is 6 possible that differential expression of this cytokine, or of specific plasticity transcripts, at early timepoints 7 might predict disease outcomes. However, the terminal nature of these analyses makes it challenging to address 8 this directly. Further studies will be required to address this issue, perhaps using IL-17 fate-mapping mice 9
(Hirota et al., 2011). 10
The elegant FCG mouse model permits one to separately consider the contributions of sex hormones and 11 sex chromosomes to biological processes (Arnold and Chen, 2009 ). This is important because, in contrast to sex 12 hormones, the role played by sex chromosomes is often less well understood (Palaszynski et al., 2005) . In 13 agreement with previous studies of active immunization EAE (Bebo et al., 1998; Palaszynski et al., 2004; 14 Trooster et al., 1996) , we found that castration of male 1C6 mice did not reduce the pathogenicity of Th17 15 derived from these animals. Thus, we exploited the FCG model to generate Tg-Sry XX and Tg-Sry XY
SryKO
16
(NOD x B6 F1) 1C6 mice, and found that Tg-Sry XY SryKO 1C6 Th17 transferred far more severe EAE to 17 NOD.Scid recipients. Thus, we show for the first time that T-cell-intrinsic, sex chromosome-encoded, factors 18 regulate sex-specific differences in Th17 cell plasticity and pathogenicity. It must be noted that the contribution 19 of male sex chromosomes is highly strain-dependent, as the XY complement is actually immunoprotective in 20 both active immunization and adoptive transfer EAE on the SJL/J strain, while sex chromosome complement 21 does not affect C57BL6/J EAE (Smith-Bouvier et al., 2008) . The interplay of sex chromosomes and hormones 22 is therefore complex and strain-specific, with different genetic backgrounds revealing distinct pathogenic or 23 regulatory mechanisms in the pathogenesis of EAE. In the case of the NOD background, sex chromosome 24 factors may interact genetically with Idd disease susceptibility loci (Wicker et al., 1995) . In further studies, it 25 will be instructive to examine the contribution of these loci to worsened Th17-mediated disease in males. 26
In an elegant recent study, it was shown that when transferred to syngeneic SJL/J hosts, splenocytes 1 from in vivo-primed male, MOG-specific, transgenic TCR 1640 mice induced progressive EAE while female cells 2 transferred RR-EAE (Dhaeze et al., 2019) . In contrast to our findings, however, male splenocytes in this model 3 did not appear to transfer disease of increased maximal severity relative to female cells. While IL-17 and IFNγ 4 production were not directly compared between transferred male and female TCR 1640 T cells, it was observed 5 that the frequency of IL-17 + IFNγ -cells diminished in males as disease progressed while the frequency of IL-17
IFNγ + increased. An important difference between this study and our own was that prior to transfer, Dhaeze and 7 colleagues stimulated splenocytes with IL-12 as well as IL-23 so as to reactivate both Th1 and Th17 cells. Thus, 8 it probable that the IL-17 -IFNγ + cells that they identified at chronic disease in males comprised a mixture of 9 both bonafide Th1 cells as well as ex-Th17 cells. By contrast, we specifically generated Th17 cells that were 10 highly Rorγt-positive prior to adoptive transfer, and male 1C6 Th17 generated under these conditions induced 11
an accelerated disease course of greater severity than that invoked by male Th1. Our data thus uncover a crucial 12 role for the Th17 compartment specifically in mediating sex differences in the severity of progressive CNS 13 autoimmunity. Further, we pinpoint a role for sex chromosome factors in regulating this dimorphism. 14 Using publicly available transcriptomics data and a bioinformatics-based approach, we have identified 3 15 genes on the X chromosome, Jarid1c, Utp14a and Pbdc1, that escape second-copy silencing in the immune 16 compartment (Berletch et al., 2015) and are additionally downregulated in pathogenic T cells. Further, we find 17 that expression of one of these genes, Jarid1c, is profoundly downregulated in male Th17 cells taken from mice 18 that experience lethal disease. Jarid1c is a histone H3K4 demethylase that promotes gene transcription when 19 binding to enhancer regions, yet represses transcription when binding to core promoter sequences (Outchkourov 20 et al., 2013) . In a recent advance, it was shown that Jarid1c has an immunomodulatory function by enforcing a 21 state of dendritic cell quiescence in collaboration with the transcriptional repressor Pcgf6 (Boukhaled et al., 22 2016). It will be important in the future to understand whether Jarid1c is a broad repressor of leukocyte 23 activation and whether its expression in dendritic cells is also regulated in a sex-specific manner. 24
While here we identified potential X-linked regulators of Th17 pathogenicity, it is important to note that 1 Y chromosome loci, such as Yaa, can strongly influence autoimmune disease (Izui et al., 1995) . A Y-2 chromosome element regulates the resistance of young SJL/J males to EAE (Spach et al., 2009) . Intriguingly, 3 the Y chromosome can have genome-wide imprinting effects: female mice display the EAE susceptibility of 4 their male sires or grandsires (Teuscher et al., 2006) potentially as a result of copy number variation of Y 5 chromosomal multicopy genes (Case et al., 2015) . It would interesting in the future to pinpoint a potential role 6 for the Y chromosome in regulating disease severity in our model, perhaps via its genetic interaction with Idd 7 loci (Wicker et al., 1995) . 8
In conclusion, we show that male Th17 cells induce severe progressive CNS autoimmunity while 9 adopting a plastic phenotype in vivo. Male Th17 pathogenesis is driven by sex chromosomal complement rather 10 than by androgens. These findings represent an important advance in our understanding of how biological sex 11 acts as a determinant of disease severity in CNS autoimmunity. Laboratories (JAX) and were bred in our animal facility. CD4 + T cells were isolated from 1C6 mice at 8-14 10 weeks of age. NOD.Scid mice were used between 9-12 weeks of age. Where required, 1C6 were 11 gonadectamized (castration/ovariectomy) or sham-operated at 3 weeks of age. For adoptive transfer of effector 12 T cells, 5x10
6 Th17 or Th1 1C6 T cells were injected i.p., in cold PBS (Cellgro) into NOD.Scid recipient mice, 13 which additionally received 200 ng of pertussis toxin (List Biological Labs) i.p. on d0 and d2 post-injection. 14 Four Core Genotype (Tg-Sry XY SryKO ) mice on the C57BL/6J (B6) background were purchased from JAX and 15 were bred to NOD or 1C6 females to obtain Tg-Sry XX and Tg-Sry XY SryKO mice. FCG B6 x NOD F1 mice 16 were actively immunized with 200 µg MOG in 100 µL of complete Freund's adjuvant (Difco) 17 supplemented with 500 µg M. tuberculosis extract (Difco), and additionally received 200 ng pertussis toxin 18 (List Biological Labs) on d0 and d2. Th1 and Th17 cells generated from FCG B6 x 1C6 mice were adoptively 19 transferred to NOD.Scid at 2.5 x 10 6 cells/recipient. All EAE mice were weighed and assessed for disease 20 symptoms daily for up to 70 days, using an established semi-quantitative scale that we have used previously 21 (Boivin et al., 2015) : 0, no disease; 1, decreased tail tone; 2, hind limb weakness or partial paralysis; 3, 22 complete hindlimb paralysis; 4, front and hind limb paralysis; 5, moribund or dead. Moribund mice were 23 euthanized with 24 hours if they did not show improvement, and were considered score 5 from that point until 24 the end of the experiment. "Disease onset" is defined as being within 24 hours of the first signs of clinical 25 symptoms. "Relapse" is defined as an increase in clinical score of ≥1 that lasts ≥2 days; "remission" as a 26 reduction of ≥1 that lasts ≥2 days (McCarthy et al., 2012) . "Rapid course" is defined as attaining ethical 1 endpoints prior to d70. A mouse was determined to have undergone chronic worsening disease if it a) increased 2 in severity of ≥1 over a 10-day period, and b) at no point during the 10-day period had a day-over-day decrease 3 of >0.5 in score, and c) never remitted after the 10-day period and d) passed a threshold of score 2.5 either 4 during or after the 10-day window. Disease was considered "relapsing/chronic" if it featured at least one 5 relapse, in addition to the initial onset, followed by progressive disease. For inflammasome inhibition 6 experiments, male mice were adoptively transferred with male Th17. Mice were alternately placed in treatment 7 (VX-765; 50 mg/kg) or vehicle (DMSO) groups upon attaining score 2. Treatment was maintained for 8 8 consecutive days. 9
10
T cell purification and culture 11
Mononuclear cell preparations were obtained from the spleens and lymph nodes (LN) of donor mice. CD4 + T 12 cells were enriched using magnetic, anti-CD4 coated beads (Miltenyi) and were subsequently incubated with 13 fluorochrome-labeled anti-CD62L. Naïve CD4 + CD62L hi T cells were purified using a FACSAria (BD) high-14 speed cell sorter and were cultured in DMEM (Life Technologies) with 10% fetal calf serum (Corning) and 15 supplemented as described (Sabatos et al., 2003) . Cells were stimulated with 2 µg mL -1 each of plate-bound 16 anti-CD3 and anti-CD28, under Th17 (3 ng mL -1 rhTGFβ + 20 ng mL -1 rmIL-6 + 20 µg mL -1 anti-IFNγ) or Th1 17 (10 ng mL -1 rmIL-12 + 10 µg mL -1 anti-IL-4) conditions. After 2 days, cells were re-plated in the absence of 18 agonistic anti-CD3/CD28 but in the presence of 20 ng mL -1 rmIL-23 (for Th17) or 10 ng mL -1 rmIL-2 (for Th1) 19 for an additional 3 days. Cells were collected and washed twice in cold PBS prior to injection. Bauer and Lassmann, 2016) . The inflammatory infiltrate, and area of demyelination, per 2 section was determined from 10 to 12 complete sections per cervical, thoracic and lumbar spinal cord and from 3 complete cross sections of the optic nerve. For inflammation we counted the average number of perivascular 4 inflammatory infiltrates per spinal cord cross sections. The area of demyelination was determined using a 5 morphometric grid (Oji et al., 2016) at an objective lens magnification of 10x in sections stained with luxol fast 6 blue by counting the number of grid points located of the area of myelin loss. The mean value per animal was 7 determined by taking the average values for all sections from a given animal. 8 9
CNS mononuclear cell isolation 10
Mice were euthanized and perfused with cold PBS administered through the left cardiac ventricle. Brains and 11 spinal cords were dissected from the skull and spinal column, respectively. CNS tissue were homogenized using 12 a PTFE Tissue Grinder (VWR) and were incubated for 30 minutes at 37°C in homogenization solution (HBSS 13 containing 4 ng mL-1 liberase and 25 ng mL-1 DNase). Homogenate were filtered through a 70 µm cell strainer, 14 
Quantitative PCR 18
RNA were isolated from purified CD4 + T cells using Direct-zol RNA Purification Kit (Zymo Research) and 19 cDNA were generated using iScript Reverse Transcriptase (Bio-Rad). qPCR was carried out on a Lightcycler 20 480 II (Roche) using Taqman validated FAM-labeled probes and Gene Expression Master Mix (Applied 21 Biosystems). Samples were run in triplicate. Rps18 was used as a housekeeping control for mouse studies 22 (Axtner and Sommer, 2009; Cooley et al., 2015) . For analysis of human CD4+ T cells, qPCR was performed on 23 reverse-transcribed cDNA using Taqman-validated probes for Jarid1c and the housekeeping genes 18S and 24 GAPDH, on a Viia7 Real-Time PCR System (ThermoFisher). The mean of 18S and GAPDH values was used a 25 reference for human studies. 26 1
Bioinformatics analysis 2
We retrieved transcriptomic data from GEO project GSE75105 (Gaublomme et al., 2015 Yosef, N., Shalek, A.K., Gaublomme, J.T., Jin, H., Lee, Y., Awasthi, A., Wu, C., Karwacz, K., Xiao, S., + events. Representative of 3 experiments. C. Female and male 1C6 Th17 were 1 adoptively transferred to sex-matched NOD.Scid recipients that were monitored for signs of EAE up to d70 2 post-transfer. A proportion of male recipients (M rapid , n=4) attained ethical endpoints before d70. No significant 3 differences in day-to-day disease score were observed between males that survived to d70 (M late , n=5) and 4 females. Φ, all mice in the group attained ethical endpoints. Representative of 4 transfer experiments. 5
Percentages in the graph legend refer to all mice studied. D-H. Female or male 1C6 Th17 were transferred sex-6 matched NOD.Scid that were sacrificed at disease onset (D, F, G) or at experimental endpoints (E, F, H) . 7
Female, n=8; Male, n=6. All male endpoint mice experienced a rapid disease course; all female endpoint mice 8 Male and female 1C6 Th17 were adoptively transferred to sex-matched NOD.Scid. Three males rapidly attained 23 ethical endpoints (M rapid potential repressors of pathogenic Th17 that are expressed on the X chromosome and that escape second-copy 22 silencing. Jarid1c (downregulated 3.2-fold in CNS-infiltrating Th17), Utp14a (7.7 fold) and Pbdc1 (2.43-fold) 23
were identified. B. Expression of putative regulators Jarid1c, Utp14a and Pbdc1 were assessed from CNS-24 A.
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